stockportfolio.pro
Stocks / ARVN vs STRO
ARVN vs STRO
Arvinas, Inc. and Sutro Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arvinas, Inc. (ARVN) | Sutro Biopharma, Inc. (STRO) | |
|---|---|---|
| Market cap | $0.5B | $0.4B |
| Revenue (latest FY) | $262.60M | $102.48M |
| Net income (latest FY) | $-80.80M | $-191.09M |
| Revenue growth (5y CAGR) | 58.9% | 19.1% |
| Net margin | -30.8% | -186.5% |
| Return on equity | -18.6% | 144.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARVN — free Open STRO — freeFrequently asked questions
Which is bigger, ARVN or STRO?
Arvinas, Inc. is larger by market capitalization — $0.5B versus $0.4B.
Which grows faster, ARVN or STRO?
Over the last five fiscal years, Arvinas, Inc. grew revenue faster — 58.9%/yr versus 19.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.